The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population by Ohyashiki, Junko H et al.
RESEARCH ARTICLE Open Access
The C allele of JAK2 rs4495487 is an additional
candidate locus that contributes to
myeloproliferative neoplasm predisposition in the
Japanese population
Junko H Ohyashiki
1*, Masayuki Yoneta
2, Hisashi Hisatomi
2, Tamiko Iwabuchi
3, Tomohiro Umezu
4 and
Kazuma Ohyashiki
3,4
Abstract
Background: Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are
myeloproliferative neoplasms (MPNs) characterized in most cases by a unique somatic mutation, JAK2 V617F.
Recent studies revealed that JAK2 V617F occurs more frequently in a specific JAK2 haplotype, named JAK2 46/1 or
GGCC haplotype, which is tagged by rs10974944 (C/G) and/or rs12343867 (T/C). This study examined the impact of
single nucleotide polymorphisms (SNPs) of the JAK2 locus on MPNs in a Japanese population.
Methods: We sequenced 24 JAK2 SNPs in Japanese patients with PV. We then genotyped 138 MPN patients (33
PV, 96 ET, and 9 PMF) with known JAK2 mutational status and 107 controls for a novel SNP, in addition to two
SNPs known to be part of the 46/1 haplotype (rs10974944 and rs12343867). Associations with risk of MPN were
estimated by odds ratios and their 95% confidence intervals using logistic regression.
Results: A novel locus, rs4495487 (T/C), with a mutated T allele was significantly associated with PV. Similar to
rs10974944 and rs12343867, rs4495487 in the JAK2 locus is significantly associated with JAK2-positive MPN. Based
on the results of SNP analysis of the three JAK2 locus, we defined the “GCC genotype” as having at least one
minor allele in each SNP (G allele in rs10974944, C allele in rs4495487, and C allele in rs12343867). The GCC
genotype was associated with increased risk of both JAK2 V617F-positive and JAK2 V617F-negative MPN. In ET
patients, leukocyte count and hemoglobin were significantly associated with JAK2 V617F, rather than the GCC
genotype. In contrast, none of the JAK2 V617F-negative ET patients without the GCC genotype had thrombosis,
and splenomegaly was frequently seen in this subset of ET patients. PV patients without the GCC genotype were
significantly associated with high platelet count.
Conclusions: Our results indicate that the C allele of JAK2 rs4495487, in addition to the 46/1 haplotype,
contributes significantly to the occurrence of JAK2 V617F-positive and JAK2 V617F-negative MPNs in the Japanese
population. Because lack of the GCC genotype represents a distinct clinical-hematological subset of MPN, analyzing
JAK2 SNPs and quantifying JAK2 V617F mutations will provide further insights into the molecular pathogenesis of
MPN.
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Myeloproliferative neoplasms (MPNs) represent a het-
erogeneous group of hematological malignancies charac-
terized by clonal hematopoiesis and an increased
number of mostly peripheral blood elements of myeloid
origin [1]. The classic Philadelphia-chromosome nega-
tive MPNs encompass three distinct diseases, namely
polycythemia vera (PV), essential thrombocythemia
(ET), and primary myelofibrosis (PMF) [2-5]. Identifica-
tion of the V617F mutation of the JAK2 gene (JAK2
V617F) led to an important breakthrough in the under-
standing of MPN disease pathogenesis [2-5]. The JAK2
V617F mutation is present in the majority of PV
patients, and about 50% of patients with ET and PMF
are affected [2-5]. Because this somatic mutation is
highly specific to MPNs, it has been designated as a
major diagnosis criterion for PV, ET, and PMF accord-
ing to the latest World Health Organization classifica-
tion of MPNs [6].
Recent investigations revealed that somatic acquisition
of genetic aberrations is one pathogenic mechanism, but
inherited genetic factors also play an important role in
the development of MPN. Several independent groups
reported that a particular JAK2 haplotype, designated
46/1 or GGCC, is strongly associated with the develop-
ment [7-9], or with MPN development, regardless of the
JAK2 mutational status [10,11]. Olcaydu et al. [12] per-
formed JAK2 haplotype analysis in familial MPNs, and
they concluded that even if JAK2 46/1 is related to the
development of MPN independent of V617F status, it
has to be regarded as only one of the genetic factors
involved in the development of MPN. Moreover, Jones
et al. [13] found correlations in JAK2 wild-type MPN
between JAK2 4 6 / 1a n db o t hM P Le x o n1 0a n dJAK2
exon 12.
In the present study, we attempted to find novel single
nucleotide polymorphisms (SNPs) of the JAK2 locus in a
Japanese population. We then examined whether JAK2
SNPs are indeed associated with a predisposition to
MPNs, especially in JAK2 V617F-positive MPNs.
Methods
Patients
In the current study conducted at the Tokyo Medical
University Hospital, 138 constitutive Japanese MPN
patients aged 30-87 years with known JAK2 V617F sta-
tus were included: 33 patients with JAK2 V617F-positive
PV, 57 patients with JAK2 V617F-positive ET, 39
patients with JAK2 V617F-negative ET, and 9 patients
with PMF. The patients experienced no familial MPNs.
We revised their classification at diagnosis according to
the latest World Health Organization classification of
MPNs. As controls, 107 healthy volunteers aged 24-86
years from the same demographic area in Japan were
used. The JAK2 V617F mutation detection system used
was reported elsewhere [14], and the JAK2 V617F muta-
tional status was categorized according to the allele bur-
den of mutated T allele. This study was approved by the
institutional review board of Tokyo Medical University
(no. 975). Written informed consent according to the
Declaration of Helsinki was obtained from all patients
prior to collection of the specimens.
PCR direct sequencing of the JAK2 locus
Genomic DNA was obtained from whole blood using an
automated system (Qiagen). To identify novel SNPs in
the JAK2 locus in this Japanese population, primer sets
for the amplification of JAK2 were designed according to
GenBank AL161450 (Figure 1A; Additional file 1A). PCR
conditions were 94°C for 30 s, 58°C for 30 s, and 72°C for
3 min for 36 cycles using High Fidelity
PLUS PCR System
dNTPack (Roche Diagnostics, Mannheim, Germany).
T h eP C Rp r o d u c t sw e r ep u r i f i e db yaH i g hP u r eP C R
Product Purification Kit (Roche Molecular Biochemical
Diagnostics, Indianapolis, IN, USA) and sequenced using
a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA) with an Applied Bio-
systems 3130 Genetic Analyzer. The obtained sequences
were compared with the JAK2 sequence.
Allele-specific PCR analysis
To determine whether minor alleles of JAK2 SNPs favor
the cis acquisition of JAK2 V617F, we performed allele-
specific analysis of six SNPs in patients with PV. The
sequence JAK2 nt51936-nt55084 (3158 bp) was ampli-
fied using forward primer int12-F and reverse primer
V617F-R or exon14-R. The primer set for the amplifica-
tion of JAK2 nt55038-nt55636 (598 bp) was forward pri-
mer V617F-F or exon14-F and reverse primer int14-R.
Both primers V617F-R and V617F-F could amplify the
Ta l l e l eo fJAK2 V617F (Figure 1B; Additional file 1A).
The PCR products were purified and sequenced as
described above.
Genotyping
Allele-specific PCR was performed with a common for-
ward primer and two allele-specific reverse primers
(Additional file 1B) using High Fidelity
PLUS PCR System
dNTPack (Roche Diagnostics) and SYBR Green I (Lonza,
R o c k l a n d ,M E ,U S A ) .T h eP C Rc o n d i t i o n sw e r e9 4 ° Cf o r
30 s, 58°C for 30 s, and 72°C for 3 min for 40 cycles using
an iCycler iQ Real-time PCR System (Bio-Rad Labora-
tories, Hercules, CA, USA). To avoid nonspecific PCR
products, melting analysis was performed by denaturing
at 95°C for 1 min and cooling to 55°C for 1 min followed
by heating at the rate of 0.5°C/10 s from 55 to 95°C.
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GraphPad Prism 5.0 software (GraphPad Software Inc.,
San Diego, CA, USA) was used for statistical analysis.
Associations with risk of MPNs were estimated by odds
ratios (ORs) and their 95% confidence intervals (95%
CIs) using logistic regression. A Mann-Whitney U-test
was used to determine the statistical significance of dif-
ferences between the control and test groups. P-values
less than 0.05 were considered to indicate statistically
significant differences. We also performed multivariate
analysis using College analysis software (version 4.5,
Fukuyama Heisei University, Fukuyama, Japan) to
exclude possible false correlation between genotype and
clinical manifestations.
Results
Minor allele frequency of SNPs from the JAK2 locus in
Japanese PV patients
We first screened for 24 SNPs of the JAK2 locus around
exons 12 to 14 in 28 Japanese patients with JAK2
V617F-positive PV from whom we obtained sufficient
DNA for this analysis (Figure 1A). Among them, minor
allele frequencies in six SNPs (rs10974944, rs12686652,
rs12335546, rs4495487, rs1028730, and rs12343867)
were significantly higher in PV patients than in healthy
volunteers (Table 1). There were no significant differ-
ences in age or sex between the PV population and
healthy controls (data not shown). Minor allele fre-
quency was estimated by total cases that had at least
one minor allele (heterozygous) or two minor alleles
(homozygous). The JAK2 SNP rs4495487, which has not
been reported previously in Caucasian populations,
showed the highest OR (13.8, 95% CI: 3.79-50.21)
among the six SNPs.
To determine whether minor alleles of JAK2 SNPs
favor the cis acquisition of JAK2 V617F, we next
sequenced six SNPs using allele-specific primers (Addi-
tional file 1A). In accordance with a previous report [8],
in the genotype with minor alleles in all six SNPs, the T
allele was more frequently observed in JAK2 V617F than
the G allele in normal controls; the OR was 7.74 (95%
CI: 2.32-25.75) (Additional file 2).
JAK2 SNP distribution in MPN patients and controls
We genotyped 138 MPN patients with known JAK2
mutational status and 107 controls for JAK2 SNP
rs449587 in addition to two SNPs that are known to be
part of the 46/1 haplotype (rs10974944 and
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Figure 1 Schematic representation of the JAK2 locus. (A) Loci of SNPs are shown as black dots. Two SNPs included in the 46/1 haplotype are
shown at the right end (rs12343867) and left end (rs10974944). A new candidate SNP is shown in the middle of those, near exon 13. Primers
used for sequencing, a forward primer (int-12F) and four reverse primers (int-12-R, exon13-R, int-13R, and int-14R), are shown. (B) Location of
primers used for allele-specific PCR. The larger fragment (3158 bp) was amplified using a forward primer (int-12F) and two sets of reverse primers
(exon14-R or V617F-R) that can discriminate two alleles with or without JAK2 V617F. The smaller fragment was amplified using two forward
primers (exon 14-F or V617F-F) and one reverse primer (int-14R). Detailed information on primers is given in Additional File 1.
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Page 3 of 8rs12343867). Overall, 95 MPN patients (68.8%) were
JAK2 V617F positive. When analyzing each MPN entity
separately, we found that 33 PV patients (100%), 57 ET
patients (63.3%), and 5 PMF patients (55.5%) were JAK2
V617F positive. The distribution of JAK2 SNPs
(rs10974944, rs4495487, and rs12343867) is listed in
Table 2. Allelic variation of three JAK2 SNPs was
strongly associated with JAK2-positive MPN (all patients
with PV, 57 patients with ET, and 5 patients with PMF)
and much less strongly associated with JAK2-negative
MPN (39 patients with ET and 4 patients with PMF). It
is notable that allelic variation of the JAK2 SNP
rs4495487 showed the highest OR in each population.
The JAK2 SNP variation in 9 PMF patients is listed in
Additional file 3. Because allelic variation of rs4495487
showed the highest OR in each patient population, we
arbitrarily named genetic variation as the “GCC geno-
type,” which has at least one minor allele in each of the
three SNPs (G allele in rs10974944, C allele in
rs4495487, and C allele in rs12343867); patients having
the 46/1 haplotype and C allele of rs4495487. The GCC
genotype is strongly associated with JAK2 V617F-posi-
tive MPNs (OR: 3.07; 95% CI: 1.73-5.46) and modestly
associated with JAK2 V617F-negative MPN (OR: 2.26,
95% CI: 1.01-4.7) compared to normal controls (Table
3). The occurrence of the GCC genotype, however, did
not depend on JAK2 V671F allele burden (Table 4).
Clinical and hematological features, JAK2 V617F, and the
GCC genotype
We compared the clinical and hematological features of
PV and ET patients with or without the GCC genotype.
We subdivided ET patients into four groups: JAK2
V617F-negative ET patients with or without the GCC
genotype and JAK2 V617F-positive ET patients with or
without the GCC genotype (Table 5). None of the JAK2
Table 1 Minor allele frequency of SNPs from the JAK2 locus in PV
No. SNP Minor alleles in PV (n = 28) Minor alleles in control (n = 28) P value* (Chi square test) Odds ratio (95% CI)
No Yes (homo/hetero) % No Yes (homo/hetero) %
1 rs10974944 (c®g) 7 21 (15/6) 75 17 11 (3/8) 39.2 0.0069 4.64 (1.49-14.55)
12 rs12686652 (c®g) 6 22 (21/1) 78.6 14 14 (5/9) 50 0.0257 3.67 (1.14-11.79)
13 rs12335546(c®t) 6 22 (21/1) 78.6 19 9 (1/8) 32.1 0.0005 7.74 (2.33-25.75)
19 rs4495487 (t®c) 7 21 (21/0) 75 23 5 (3/2) 17.8 < 0.0001 13.8 (3.79-50.21)
22 rs1028730 (g®a) 6 22 (21/1) 78.5 19 9 (2/7) 32.1 0.0005 7.74 (2.33-25.75)
24 rs12343867(t®c) 7 21 (21/0) 75 17 11 (4/9) 39.3 0.0069 4.64 (1.48-14.55)
* P values were calculated by the cases having minor alleles (homozygous and heterozygous) and cases without minor alleles.
Table 2 Genotype-specific association of SNPs from the JAK2 locus in MPN
Case population Control population SNP P Genotype
¶ Odds ratio (95% CI)
Major Hetero Homo Major vs Hetero Major vs Homo
JAK2 V617F-positive PV Healthy volunteers rs10974944 0.0126* CC CG GG 2.75 (1.06-7.14)* 4.24 (1.51-11.92)*
(n = 33) Japanese (n = 107) rs4495487 < 0.0001* TT TC CC 4.26 (1.56-11.61)* 11.31 (3.60-35.57)*
rs12343867 0.0032* TT TC CC 2.26 (0.88-5.77) 5.683 (1.98-16.35)*
JAK2 V617F-positive ET Healthy volunteers rs10974944 0.0371* CC CG GG 2.42 (1.20-4.92)* 1.10 (0.40-3.02)
(n = 57) Japanese (n = 107) rs4495487 0.0009* TT TC CC 3.97 (1.86-8.49)* 4.00 (1.44-11.14)*
rs12343867 0.0013* TT TC CC 3.52 (1.68-7.38)* 3.55 (1.33-9.52)*
JAK2 V617F-negative ET Healthy volunteers rs10974944 0.068 CC CG GG 2.58 (1.14-5.84)* 1.49 (0.50-4.46)
(n = 39) Japanese (n = 107) rs4495487 0.0097* TT TC CC 3.28 (1.45-7.43)* 3.05 (0.95-9.58)
rs12343867 0.112 TT TC CC 2.26 (1.01-5.04)* 2.08 (0.67-6.40)
JAK2 V617F-positive MPN Healthy volunteers rs10974944 0.0138* CC CG GG 2.42 (1.29-4.55)* 2.24 (1.03-4.88)*
(PV, ET, and PMF, n = 95) Japanese (n = 107) rs4495487 < 0.0001* TT TC CC 4.08 (2.13-7.84)* 6.88 (2.88-16.41)*
rs12343867 0.0002* TT TC CC 2.89 (1.53-5.45)* 5.54 (2.35-13.06)*
JAK2 V617F-negative MPN Healthy volunteers rs10974944 0.1961 CC CG GG 2.01 (0.92-4.37) 1.14 (0.39-3.37)
(PV, ET, and PMF, n = 43) Japanese (n = 107) rs4495487 0.024* TT TC CC 2.79 (1.28-6.08)* 2.48 (0.78-7.80)
rs12343867 0.3069 TT TC CC 1.78 (0.82-3.84) 1.63 (0.58-4.94)
JAK2 V617F-positive MPN JAK2 V617F-negative MPN rs10974944 0.5493 CC CG GG 1.21 (0.55-2.66) 1.82 (0.70-5.35)
(PV, ET, and PMF, n = 95) (PV, ET and PMF, n = 43) rs4495487 0.1762 TT TC CC 1.46 (0.66-3.31) 2.78 (0.93-6.29)
rs12343867 0.1572 TT TC CC 1.62 (0.72-3.61) 2.71 (0.93-7.90)
P based on chi-square test. Asterisks indicate statistically significant values.
¶Genotype was divided into three groups. Major: no existence of minor allele; Hetero: existence of one minor allele; Homo: existence of two minor alleles.
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had thrombosis (p = 0.0446), and splenomegaly was
more frequently seen in this subset of ET patients (p =
0.0448), indicating that JAK2 V617F-negative ET with-
out genetic variation shows a distinct clinical feature.
White blood cell counts were significantly elevated in
patients with JAK2 V617F-positive ET, regardless of
GCC genotype status (p = 0.0399) (Figure 2A). Hemo-
globin levels were significantly elevated in patients with
both JAK2 V617F and the GCC genotype compared to
those with the GCC genotype but lacking JAK2 V617F
(p = 0.002) (Figure 2B). There was no significant differ-
ence in platelet counts among the four groups. These
results indicate that the proliferative nature of MPNs,
such as increased white blood cell and hemoglobin
counts, may be linked to JAK2 V617F, regardless of
JAK2 genetic variations.
Because all the PV patients in the current study were
JAK2 V617F positive, we compared the clinical and
hematological features between PV patients with or
without the GCC genotype (Table 6). Although there
were no significant differences in age, sex, clinical mani-
festations, or survival between the two groups, platelet
count was significantly elevated in PV patients without
the GCC genotype (p = 0.015) (Figure 2). These findings
suggest that germline genetic variation also affects PV
patients.
Discussion
This is the first study to provide evidence of an associa-
tion between somatic JAK2 V617F mutation and JAK2
SNPs in a Japanese population of MPN patients. We
found a candidate SNP, rs4495487, that may contribute
to MPN phenotype in this population. A contribution of
this SNP has not been reported in Caucasian popula-
tions; however, because it is located between rs1097944
and rs12343867, rs4495487 might be included in the 46/
1 haplotype. As in previous reports, we found a signifi-
cant association between JAK2 SNPs and MPN pheno-
type in JAK2 V617F-positive MPNs [7-9] and in JAK2
V617F-negative MPNs [10,11].
Although the occurrence of JAK2 V617F greatly contri-
butes to the diagnosis of MPNs, it remains unclear why
this single genetic change represents at least three clinical
phenotypes (i.e., PV, ET, and PMF). It also remains
uncertain whether JAK2 V617F is the primary genetic
change responsible for MPNs. Thus, the major obstacle
to clarifying the molecular pathogenesis of MPNs is the
substantial complexity of the genetic changes, including
germline genetic variation of the JAK2 locus.
In the present study, we demonstrated an association
between germline genetic variation in the JAK2 locus
and MPN phenotype in a Japanese population. Although
the clinical manifestation largely depends on JAK2
V617F mutation rather than SNPs in the JAK2 locus of
ET patients, we noted that JAK2 V617F-negative ET
without the GCC genotype showed a distinct clinical
feature, suggesting an underlying genetic change that
has not yet been identified. Tefferi et al. [11] demon-
strated that nullizygosity for the JAK2 46/1 haplotype is
associated with inferior survival. Taken together, these
findings suggest that the lack of certain germline genetic
Table 3 Summary of the JAK2 genotype in MPN patients
GCC genotype non-GCC genotype P (Chi-square test) Odds
ratio
95% CI
Case Population 46/1 haplotype rs4495987
(+)
non-46/1 haplotype rs4495987
(-)
JAK2V617F-positive PV (n = 33) 22 11 0.0023 3.63 1.59-
8.29
JAK2V617F-positive ET (n = 57) 35 22 0.0043 2.72 1.40-
5.32
JAK2V617F-negative ET (n = 39) 24 15 0.0076 2.91 1.36-
6.19
JAK2V617F-positive MPN (n = 95) 60 35 0.0001 3.07 1.73-
5.46
JAK2V617F-negative MPN (n = 43) 24 19 0.0289 2.26 1.01-
4.70
Control: non-MPN (n = 107) 38 69
Table 4 JAK2 V617F allele burden and GCC genotype
Category Genotype JAK2 V617F allele
burden
P value
negative < 20% 20-80% > 80%
PV GCC (-) 0 0 7 3
GCC (+) 0 0 18 5
ET GCC (-) 17 8 14 1 0.4198
GCC (+) 22 14 15 5
PMF GCC (-) 4 1 1 0
GCC (+) 0 0 2 1
MPN GCC (-) 21 8 22 4 0.6815
GCC (+) 22 15 36 10
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of MPNs. In a study by Trifa et al. [15], the 46/1 haplo-
type was associated with mutant allele burden > 50% in
JAK2 V617F-positive MPN patients. However, we could
not find any relationship between allele burden and
germline genetic variations. Although we found an asso-
ciation between splenomegaly and JAK2 V617F-negative
ET without the GCC genotype, a previous report by
Vannucchi et al. [16] demonstrated JAK2 V617F muta-
tion was related to larger spleen size in ET. In addition,
we found no significant differences in platelet count
among the ET groups, unlike previous reports [16,17].
These discrepancies could be related to differences in
the size or ethnics of the analyzed patient cohorts.
Therefore, larger studies of Japanese patients should be
conducted to clarify the association between JAK2 V617
allele burden and JAK2 haplotype.
According to a recent report by Colaizzo et al. [18], in
patients with splanchnic venous thrombosis, the JAK2
V617F mutation is frequently found in women and, when
interacting with the 46/1 haplotype, it may represent a
gender-related susceptibility allele for splanchnic venous
thrombosis. In the current study, we found no relation-
ships between sex or genotype and the occurrence of
thrombosis. However, future research should clarify
whether sex modulation of those genetic changes also
occur in Asian populations. In the present study, none of
the JAK2 V617F-negative ET patients without the GCC
genotype had the complication of thrombosis. Smalberg et
al. [19] recently demonstrated that the 46/1 haplotype is
associated with the development of JAK2 V617F-positive
splenic vein thrombosis (SVT), but the existence of JAK2
V617F-negative SVT patients also indicates an important
role for the 46/1 haplotype in the etiology and diagnosis of
SVT-related MPNs. In contrast, Kouroupi et al. [20]
showed that the 46/1 haplotype is not a susceptibility
locus for the development of SVT. Thus, further explora-
tion is required to clarify whether the JAK2 germline varia-
tion is a risk factor of thrombosis. It is notable that platelet
count was significantly higher in PV patients without the
GCC genotype. Although this is partially due to the rela-
tive iron deficiency during the expansion of the PV clone,
these findings suggest that a lack of germline genetic varia-
tion (i.e., nullizygosity) may be linked to disease severity.
There is mounting evidence of genetic causes of MPN
initiation and progression besides JAK2 and MPL, which
define the MPN phenotype [21-28]. Deletion or muta-
tion of TET2, associated with deletion and UPDs of
chromosome 4q, have been reported in 10-12% of
MPNs with or without JAK2 V617F [23,28,29]. Mutation
of ASXL1 in CD34-positive purified cells strongly sug-
gests that this is an early genetic event closely related to
epigenetic status [24]. Ernst et al. [25] reported that
EZH2, which encodes the catalytic subunit of the poly-
comb repressive complex (PRC2), is mutated in a subset
of MPNs; EZH2 also influences stem cell renewal by
epigenetic repression of genes involved in cell fate deci-
sions. In contrast, mutation of IDH is frequently found
in blast-phase MPNs [26]. Therefore, investigation of
other oncogenic mutations in MPN patients and their
associations with germline gene variants might help to
reveal the mechanism underlying the relationship
between haplotype variants and somatic mutability.
Conclusions
In conclusion, we demonstrated that the C allele of the
JAK2 rs4495487 is an additional candidate locus that
contributes to MPN predisposition in the Japanese
Table 5 Demographic and clinical characteristics of ET patients
JAK2 V617F negative JAK2 V617F positive
GCC genotype GCC genotype P value
No (n = 19) Yes (n = 23) No (n = 22) Yes (n = 35)
Age, mean (SD) 51.2 (18.3) 57.9 (17.5) 64.8 (14.9) 66.1 (16.2) 0.6466
Sex
Female 10 (52.6%) 14 (60.9%) 8 (36.4%) 22 (62.9%) 0.2965
Male 9 (47.4%) 9 (30.1%) 14 (64.6%) 13 (37.1%)
Splenomegaly 11/16 (68.8%) 4/22 (18.2%) 5/20 (25%) 4/33 (12.1%) 0.0448*
Thrombosis 0/11 (0%) 5/21 (23.8%) 6/17 (35.3%) 7/30 (23.3%) 0.0446*
Therapy requirement 10/16 (90%) 15/22 (68.2%) 7/21 (33.3%) 25/34 (73.5%) 0.7408
Cytogenetic abnormality 1/8(0%) 0/16 (0%) 2/9 (22.2%) 4/21(19%) 0.3618
MF evolution 0/16 (0%) 1/22 (4.5%) 0/15 (0%) 1/30 (3.3%) 0.3787
AML evolution 0/11 (0%) 1/22 (4.5%) 0/15 (0%) 0/30 (0%) 0.7343
Survival, mean (SD) 2036 (2267) 1883 (1643) 1706 (1847) 1717 (292) 0.6528
Statistical analysis was done among four groups.
P value is obtained from multivariate analysis.
Asterisks indicate statistically significant values.
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too small to draw a definitive conclusion, our results
provide novel insights into the molecular pathogenesis
o fM P N s .T oc l a r i f yt h ep a t h o p h y s i o l o g yo fM P N s ,i t
will be necessary to analyze JAK2 SNPs as a MPN pre-
disposition, quantify JAK2 V617F mutations as a hall-
mark of MPN phenotype, and identify other germline
variants and somatic mutations, including TET2, in a
large number of patients.
Additional material
Additional file 1: Primers used in this study. (A) Primers used for PCR-
direct sequencing. Primers 1, 7, 8, 9, and 10 were also used for allele-
specific PCR to discriminate JAK2 V617F-positive and -negative alleles. (B)
Primers used for SNP analysis in 138 MPN patients and 107 healthy
controls.
Additional file 2: Six SNPs of the JAK2 locus in PV patients and
normal controls. Six SNPs were sequenced using allele-specific primers
(Additional File 1A). In normal controls, detected SNPs were located in
the allele without JAK2 V617F mutation. In PV patients, detected SNPs
were located in the mutated T allele of JAK2. The genotype that had
minor alleles in all six SNPs was designated as the GGTCAC genotype.
This genotype is more frequently observed in T allele of JAK2 V617F (19/
28, 67.9%) than G allele in normal controls (6/28, 21.4%); the odds ratio
was 7.74 (95% CI: 2.32-25.75). There were no significant differences in age
or sex between normal controls and patients with PV.
Additional file 3: JAK2 SNP distribution in 9 patients with PMF.W e
could not statistically analyze the possible association between
genotypes and clinical manifestations because of the small number of
PMF patients in this single-institution study, however, results of
genotypic analysis are shown in this table.
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